Aeromonas species cause both intestinal and extraintestinal disease. We reviewed hospital laboratory and medical records to identify patients with Aeromonas infection of the hepatobiliary or pancreatic system. Analysis of data from our hospital, as well as a review of the published literature, yielded a total of 41 episodes in 39 patients, and the features of these episodes are described. The most common manifestation of Aeromonas hepatobiliary infection among all reported cases was cholangitis (29 of 41 episodes). The majority of infections in our hospital occurred in patients with underlying immunosuppression or malignancy (13 of 15 patients), including 4 liver transplant recipients, and nosocomial infection was not infrequent (8 of 17 episodes). Infection occurred most commonly in patients with obstruction of the biliary tract due to stones, tumor, or stricture and was associated with a relatively high mortality rate (11.8%). Antibiotic susceptibility testing revealed that gentamicin, imipenem, and ciprofloxacin had the highest activity against the Aeromonas species isolated.
stones, stricture, or tumor or clinical and laboratory evidence of pancreatitis with pseudocyst formation; and (3) bile, pancreatic fluid, or blood cultures positive for Aeromonas species. A search of the hospital database was also performed to identify the total number of patients admitted to the hospital with cholangitis during the study period using the International Classification of Diseases, Ninth Revision diagnosis code for cholangitis. From these data, the percentage of all episodes of cholangitis due to Aeromonas species was determined.
Data on clinical and demographic characteristics were obtained retrospectively by review of patient medical records. Cases were identified as either community acquired or nosocomial. The latter was defined as having occurred 124 h after admission, with signs and symptoms of infection that were absent at the time of admission [9] . Nosocomial postoperative Aeromonas infections were those acquired within 30 days after a surgical procedure [9, 10] , including percutaneous transhepatic cholangiography tube placement or manipulation. Of note, prophylaxis with ampicillin-sulbactam (or clindamycin and gentamicin, for penicillin-allergic patients) was routinely provided before performance of percutaneous transhepatic cholangiography tube placement. Aeromonas infections occurring within 72 h after a procedure such as endoscopic retrograde cholangiopancreatography (ERCP) [11] or liver biopsy, were also considered to be nosocomial [9, 10] . Aeromonas species were isolated on blood agar and identified to the species level by means of standard biochemical testing. Antimicrobial susceptibility testing of Aeromonas isolates was performed by the hospital microbiology laboratory via the disk diffusion technique for nonblood isolates, and MICs were determined via microtiter broth dilution for blood isolates, according to the guidelines of the NCCLS [12, 13] .
A search of MEDLINE for articles published from January 1960 through December 2000 was performed to identify additional cases of hepatobiliary or pancreatic Aeromonas infection published in the English-language literature. The keyword "Aeromonas" was cross-referenced with the keywords "liver," "biliary," "gallbladder," "pancreas," "pancreatic pseudocyst," "cholangitis," "cholecystitis," and "liver transplantation." Secondary references were also reviewed.
RESULTS
Aeromonas species were isolated from 126 patients at UMHS during the 7-year study period. In 15 (12%) of these patients, Aeromonas infection was determined to be of hepatobiliary or pancreatic origin (table 1) . Two patients experienced 2 episodes of Aeromonas infection each (patients 4 and 5); the first patient's episodes were separated by 1 year and the second patient's by 22 months. Cholangitis accounted for the majority of episodes of Aeromonas hepatobiliary or pancreatic infection (13 of 17 episodes). In total, 980 patients with cholangitis were admitted to the hospital during the same period, and Aeromonas infection of the biliary tract accounted for 1.3% of all hospital admissions for cholangitis.
Patients with Aeromonas hepatobiliary or pancreatic infection ranged in age from 18 months to 81 years; 10 patients were male and 5 patients were female. There were 16 episodes of Aeromonas infection of the biliary tract and 1 case of infection of a pancreatic pseudocyst. All cases of infection occurred in patients with bile or pancreatic duct obstruction. The causes of obstruction were variable and, in some patients, multiple. These causes included cholelithiasis or choledocholithiasis (7 of 15 patients), cholangiocarcinoma (3 of 15), pancreatic cancer (3 of 15), nonmalignant biliary stricture (6 of 15), and necrotizing pancreatitis (1 of 15). Patient 1 was the only patient without biliary or pancreatic duct obstruction at the time of presentation, but he developed an infected biloma after complications due to a cholecystectomy for the treatment of cholelithiasis. It is unknown whether Aeromonas organisms might have been present at the time of the cholecystectomy.
Underlying illnesses included malignancy of the pancreas or biliary tree, which was present in 6 patients, and other immunosuppressive medical conditions, which were present in slightly more than one-half of the patients: 3 of 15 patients had diabetes mellitus, 4 were liver transplant recipients, and 1 had undergone splenectomy. Only 2 patients had neither malignancy nor any other immunosuppressive condition (patients 1 and 8). Recurrent episodes of Aeromonas cholangitis occurred in 1 liver transplant recipient and in 1 patient with diabetes mellitus.
Stool specimens were generally not obtained for culture, but a review of the medical charts did not reveal any clear evidence for gastroenteritis preceding any of the episodes of Aeromonas infection. There was also no documentation of obvious environmental exposures for patients, such as contact with bodies of water. Eight (47%) of 17 episodes of Aeromonas infection were classified as nosocomial; infection occurred after surgery in 2 patients, after liver biopsy or ERCP in 2 patients, and after percutaneous drain manipulation or placement in 4 patients.
Aeromonas hydrophila was identified in all instances in which species identification was performed (10 of 17 episodes). Except for 1 episode (in patient 8), all Aeromonas infections were polymicrobial, regardless of whether isolates were obtained from blood samples or from samples from the pancreatic or biliary systems. Enterobacteriaceae, Enterococcus species, streptococci, Pseudomonas aeruginosa, and yeast were isolated in association with Aeromonas species, which suggests that the infections had an intestinal source. Antibiotic susceptibility data were available for 22 different strains of Aeromonas isolated. No isolates were susceptible to ampicillin or cefazolin, and ampicillin-sulbactam was active against only 13% of isolates. Cefotetan, cefotaxime, and trimethoprim-sulfamethoxazole were active against 71%, 67%, and 54% of isolates, respectively, and 44% of isolates were susceptible to piperacillin. In vitro, the most reliably active agents were gentamicin (86%), imipenem (100%), and ciprofloxacin (90%).
Two patients, both of whom were liver transplant recipients, developed septic shock as a complication of infection. They were also the youngest patients in the group. Three other cases were complicated by liver abscesses. Two patients died as a direct result of progressive infection (patients 6 and 12), resulting in a mortality rate of 11.8% for 17 episodes. In 3 other patients (patients 9, 11, and 13), infection likely hastened death, which was primarily associated with end-stage malignancy, resulting in an overall mortality rate of 29% for 17 episodes. The remainder of the patients responded well to antimicrobial therapy and, when such procedures were necessary, to biliary tract or abscess drainage. Of note, the 5 patients who died had received antibiotics to which all their bacterial isolates (including Aeromonas isolates) were susceptible. Of the cured patients whose Aeromonas isolates were tested for susceptibility to the antimicrobial agent or agents received ( ), all had received n p 9 at least 1 agent active against the Aeromonas strain or strains isolated, although, in some cases, the only effective agent was an aminoglycoside. It is interesting to note that, of the patients with nosocomial cases of Aeromonas infection, patients 1, 12, and 15 had received ampicillin-sulbactam perioperative periprocedure prophylaxis and had developed Aeromonas infection with isolates resistant to that agent. Ampicillin-sulbactam susceptibility was not tested for the Aeromonas isolates recovered from the other patients with nosocomial cases of infection.
We subsequently reviewed cases of hepatobiliary or pancreatic Aeromonas infection described in the English-language literature for which abstracts were included in MEDLINE. Cases with insufficient data for analysis or pooled summary findings [1, 7, 8, [14] [15] [16] [17] [18] [19] [20] [21] and cases involving isolation of Aeromonas species from wounds, bile drainage tubes, or postmortem specimens in the absence of clinical signs of primary hepatobiliary tract infection [22] [23] [24] [25] [26] were excluded. There were 24 additional cases (1 episode each in 24 patients) in the literature that provided sufficient clinical and microbiological data for analysis [22, [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] . Of these cases, 63% occurred in males, and the age range of the patients was 5 months to 93 years (15 of 24 patients were aged у60 years). As in the patients identified at our hospital, obstruction of the biliary tract was a frequent predisposing risk factor for Aeromonas infection (table 2) . Among reports in which such information was provided, cholelithiasis, pancreatic carcinoma, and cholangiocarcinoma were the most common causes of biliary obstruction. Lack of a predisposing condition was unusual. Cirrhosis was also associated with infection, although we did not observe this in our patient population. Furthermore, unlike our patient series, few cases were believed to be nosocomial. Two cases reported by Janda et al. [22] were classified as nosocomial, although no details were provided about whether these cases occurred after the patients underwent a surgical procedure.
The clinical syndromes associated with Aeromonas infection in all 41 episodes were reviewed. In addition to the 13 episodes of cholangitis in our patient population, a diagnosis of cholangitis due to Aeromonas species was made in 16 (67%) of 24 episodes found in the literature. Therefore, 29 (71%) of 41 episodes manifested as cholangitis. Isolated cholecystitis was present in a total of 9 (22%) of 41 episodes, with a high rate of complication: empyema in or gangrene of the gallbladder occurred in 5 of these 9 episodes. Likewise, complication due to abscess in or around the liver was not uncommon (9 [22%] of 41 episodes). There were no additional cases described in the literature of Aeromonas infection in a pancreatic pseudocyst.
Finally, similar to the findings in our 17 episodes, the isolation of pathogens in addition to Aeromonas species was a frequent occurrence. Such copathogens were typically enteric bacteria. Furthermore, among cases reported in the literature in which species identification of Aeromonas isolates was performed, A. hydrophila was the predominant species and was recovered from 14 of 21 patients. Aeromonas veronii biotype sobria was recovered from 2 patients and Aeromonas caviae from 6 (both A. hydrophila and A. caviae were recovered from 1 patient [37] ). Outcomes were reported for 21 of 24 patients; 17 of 21 survived the episode of Aeromonas infection. Thus, Downloaded from https://academic.oup.com/cid/article-abstract/37/4/506/331045 by guest on 26 September 2019 the overall mortality rate for 38 episodes in which outcome was known was 24%.
DISCUSSION
Aeromonas species are oxidase-positive, facultatively anaerobic, flagellated gram-negative rods whose natural habitat is freshwater or brackish water [39] . Aeromonads have also been isolated from chlorinated tap water, including hospital water supplies, and soil [2, [40] [41] [42] . Aeromonas species are not commonly found among the normal gastrointestinal flora, but there are reports of the isolation of Aeromonas organisms from stool samples obtained from healthy, asymptomatic persons [43] . Asymptomatic intestinal carriage is thought to represent transient colonization; rates range from !1% to 3% [2, 44, 45] .
In persons from tropical and subtropical climates, asymptomatic Aeromonas colonization rates may reach 30% [43, 46] . In Asian countries, this may be associated with increased human participation in water-related occupations and activities [46] and frequent contamination of seafood with Aeromonas species [18, 47] . Aeromonas infection rates may also be higher in Asia than in the United States [20, 21] . The prevalence of recurrent pyogenic cholangitis may contribute to the increased incidence of Aeromonas infection. This syndrome, which is common in and unique to Southeast Asia [16, 18] , is characterized by obstruction of the biliary tract and secondary sepsis and is likely due to a high rate of infection with biliary parasites, which cause stricture and stone formation. Aeromonas infection has been noted as a complication of pyogenic cholangitis [7, 16, 18, 21, 48] . In fact, much of the literature describing the association of Aeromonas infection with hepatobiliary or pancreatic infection has originated in Asia [7, 16, 18, 21] . However, there are limited details in these reports with regard to clinical manifestations of hepatobiliary disease, outcome, culture data, and clinical and demographic characteristics of patients and whether patients had primary hepatobiliary infection.
Aeromonas infection has been noted to occur in patients with underlying diseases, such as cancer [6, 7, 14, 15] and diabetes mellitus, and in patients receiving immunosuppressive medications, such as chemotherapeutic agents and corticosteroids [6, 7, 25, 26] . In our series of patients, malignancy or other immunosuppressive conditions were seen in 24 (62%) of 39 patients (table 2) . Although we found that only 1.3% of all hospital admissions for cholangitis were the result of Aeromonas infection, in the subset of patients with biliary tract or pancreatic malignancy, this percentage may be significantly higher. Furthermore, our series contains the first reports of hepatobiliary Aeromonas infection after liver transplantation. Three of the 4 liver transplant recipients with Aeromonas infection had developed biliary stricture as a postoperative complication of transplantation. Two patients experienced septic shock as a complication of infection, although, because both patients had polymicrobial infection, it was difficult to attribute complications to a particular organism.
Aeromonas organisms are also well-recognized pathogens in patients with liver disease [7, 8, 41, 49] . Because there does not appear to be an alteration in the lower intestinal bacterial flora of patients with cirrhosis [50] , Aeromonas species may be particularly virulent in these patients; such species account for a larger percentage of cases of gram-negative bacteremias in patients with cirrhosis than in those without cirrhosis [7, 49] .
Overall, in this series, 10 of 30 cases were classified as nosocomial. The association between Aeromonas species and nosocomial infection has been described in other reports [7, 8, 14, 15, 21, 26, 37, 46] . Unlike community-acquired infection, which occurs in patients who consume contaminated water or have a traumatic wound that comes into contact with contaminated soil [3, 26] , the source of infection in nosocomial cases is often unknown and is presumed to be infection or transient colonization of the gastrointestinal tract [2, 6, 7, 16] . The frequent isolation of Aeromonas species in association with Enterobacteriaceae, streptococci, and enterococci lends support to this theory. In fact, the isolation of copathogens in cases of Aeromonas infection is quite common, with case series describing 32%-89% of Aeromonas infections as polymicrobial [3, 7, 26, 46] . Typical accompanying pathogens have included gramnegative aerobic bacilli, such as Escherichia coli, Klebsiella pneumoniae, Enterobacter species, and Pseudomonas species, as well as gram-positive cocci, including Enterococcus species and Staphylococcus species. It is, of course, difficult to assess the contribution of each organism to disease in patients with polymicrobial infection.
Bacteria may enter the biliary tract by ascending from the gastrointestinal tract, although hematogenous spread via portal venous blood may also play a role [51] . The question has been raised of whether pancreatic or biliary instrumentation may facilitate Aeromonas infection of the hepatobiliary tract [18, 37, 46] . Sphincterotomy and biliary stenting are recognized risk factors for contamination of the biliary tract with bacteria [51] , and Aeromonas organisms may gain access to the biliary tree via this route if they are present in the gastrointestinal tract. One patient in our series (patient 12) had undergone ERCP 2 days before the onset of infection, and, similarly, Kelly et al. [46] described a 55-year-old man with pancreatic cancer who developed Aeromonas sepsis 1 day after undergoing ERCP.
Whether specific strains of Aeromonas have a predilection for causing extraintestinal disease-and, specifically, hepatobiliary or pancreatic disease-is unknown. A. hydrophila and Aeromonas veronii are believed to be more virulent than A. caviae, and variations in virulence potential within species have been shown to exist [20] . However, the actual factors regulating invasion by Aeromonas species are unknown. Chan et al. [18] noted more antimicrobial resistance among strains of Aeromonas recovered from bile specimens than among those recovered from fecal specimens. Like other enteric pathogens, Aeromonas species are resistant to the bacteriostatic actions of bile [52] .
The overall mortality rate among patients in our series for whom outcome was reported was 9 (24%) of 38 episodes. However, it is difficult to tell whether death was directly associated with Aeromonas infection in these episodes. The sepsisrelated mortality rate for Aeromonas species has been as high as 57% in some series [2] , although, in more recent series, mortality rates have been ∼30% [1, 7, 8, 16, 20, 21] . Patients with malignancy may have higher mortality rates than do those with other underlying diseases [14, 16, 21] .
The antibiotic susceptibility patterns of our isolates are typical of those reported by others [7, 53, 54] . Aeromonas species produce a b-lactamase [24, 54] , which makes them resistant to ampicillin and first-generation cephalosporins [20] . The use of a b-lactamase inhibitor, such as sulbactam, may not restore antibiotic susceptibility [7, 16, 53, 54] , and, in fact, ampicillinsulbactam had poor activity against isolates in our series. Aeromonas isolates from Asia have been noted to be less frequently susceptible to certain agents, such as tetracyclines and trimethoprim-sulfamethoxazole [7, 54] , and, more recently, to piperacillin, imipenem, and third-generation cephalosporins [8, 18] . In addition, Aeromonas organisms appear to have reduced susceptibility to tobramycin, compared with other aminoglycosides [36, 53, 54] . These findings have particular significance when the choice of antimicrobial agents to administer for empirical treatment of biliary tract infection is being considered. Antibiotics such as ampicillin-sulbactam, piperacillin, or cefotetan, which are often administered to empirically treat intraabdominal infections, may be ineffective if Aeromonas species are present. Furthermore, clinical characteristics are not specific enough to differentiate sepsis due to Aeromonas organisms from that due to other gram-negative bacilli [7, 21] .
In summary, Aeromonas species are an important cause of hepatobiliary and, occasionally, pancreatic infection. Patients with impaired biliary drainage due to stone formation, malignancy, or surgical procedures (including liver transplantation) are at particular risk for this problem. There is often no history of diarrhea or ingestion of contaminated food or water, and some cases may be nosocomially acquired. Infection is often polymicrobial, and the overall mortality rate in our series was 24%. The antimicrobial agents most active against Aeromonas are third-generation cephalosporins, imipenem, and quinolones.
